Trending...
- California prioritized fighting organized retail theft, those results are paying off with 36,000 arrests and $293 million in stolen goods recovered - 117
- California and the Australian state of Queensland ink new partnership to accelerate climate resilience, agricultural technology, and innovation - 112
- California's public safety strategy works: Governor Newsom's commitment helps lower crime as new study shows violence prevention saves lives
IRVINE, Calif. and LONDON, July 22, 2024 ~ London, UK - Medical and Commercial International Limited (MCI), a leading specialized liability underwriting company, has joined forces with GATC Health Corp, a technology company utilizing artificial intelligence in drug discovery, to launch a groundbreaking program that will revolutionize the financing of clinical trials. This first-of-its-kind initiative, approved by Lloyd's of London, will provide insurance coverage for biotech companies in the event of trial failure.
The partnership between MCI and GATC Health aims to mitigate the financial risks associated with medical innovation and research. By utilizing GATC Health's proprietary AI technology, which accurately forecasts clinical trial endpoints, this new insurance model will significantly enhance risk assessment and promote the growth of therapeutic drug development.
MCI CEO Phil Trafford expressed excitement about this new venture, stating that "clinical trial funding insurance is a revolutionary product with high demand in the market." He believes that working alongside lenders and investors, this program will not only support medical innovation but also provide unparalleled risk assessment accuracy.
More on The Californer
The biotech industry has long struggled with securing funding for drug development projects without compromising equity or control of their company. This new program addresses these challenges by utilizing GATC Health's technology to enhance the risk selection process and bring more therapeutic drugs to market.
Ben Canagaretna, Global Managing Director of Acrisure Re Corporate Advisory & Solutions (ARCAS), an international financing and consulting firm responsible for program sales and distribution, praised GATC Health's AI technology for enabling this unique combination of financing and insurance. He also noted that the response from biotech companies and large brokerage firms has exceeded expectations, highlighting the pent-up demand for innovative financing programs.
GATC Health CEO John Stroh emphasized their focus on using AI technology to develop safer and more effective drugs in less time and with less money. Through their partnership with MCI backed by Lloyd's of London, they aim to transform the financial model of drug development and bring better treatments to those in need.
More on The Californer
This collaboration between MCI and GATC Health, with the backing of Lloyd's, marks a significant development in the insurance industry. It promises to reshape the landscape of clinical trial funding and provide stakeholders in the biotech industry with enhanced risk management tools to unlock groundbreaking medical innovations.
GATC Health's Multiomics Advanced Technology™ (MAT) platform, which utilizes AI and machine learning to simulate human physiology, has already shown promising results. In just two years, it has discovered and tested seven drug candidates with the potential to create 10 to 12 novel molecules each year. With this technology, the likelihood of clinical trial success is significantly increased.
The launch of this program marks a new era in clinical trial financing, where innovative technology and insurance come together to support medical innovation and bring life-changing treatments to those who need them most. With Lloyd's endorsement, this partnership between MCI and GATC Health is set to transform the drug development landscape for years to come.
The partnership between MCI and GATC Health aims to mitigate the financial risks associated with medical innovation and research. By utilizing GATC Health's proprietary AI technology, which accurately forecasts clinical trial endpoints, this new insurance model will significantly enhance risk assessment and promote the growth of therapeutic drug development.
MCI CEO Phil Trafford expressed excitement about this new venture, stating that "clinical trial funding insurance is a revolutionary product with high demand in the market." He believes that working alongside lenders and investors, this program will not only support medical innovation but also provide unparalleled risk assessment accuracy.
More on The Californer
- Over 120 Teen Volunteers To Help At 8th Annual Santa Barbara County Farm Day
- Bestselling "Akiti the Hunter" Series Launches National and International Push to Open Libraries
- New Book Brings Decades of Clinical Research to the Addiction Recovery Crisis
- Apple Valley Home Sales Rise 22.0% as Active Listings Fall 20.2%
- Banafsheh Sayyad Offers a Free Sacred Dance Experience to Awaken Focus and Presence
The biotech industry has long struggled with securing funding for drug development projects without compromising equity or control of their company. This new program addresses these challenges by utilizing GATC Health's technology to enhance the risk selection process and bring more therapeutic drugs to market.
Ben Canagaretna, Global Managing Director of Acrisure Re Corporate Advisory & Solutions (ARCAS), an international financing and consulting firm responsible for program sales and distribution, praised GATC Health's AI technology for enabling this unique combination of financing and insurance. He also noted that the response from biotech companies and large brokerage firms has exceeded expectations, highlighting the pent-up demand for innovative financing programs.
GATC Health CEO John Stroh emphasized their focus on using AI technology to develop safer and more effective drugs in less time and with less money. Through their partnership with MCI backed by Lloyd's of London, they aim to transform the financial model of drug development and bring better treatments to those in need.
More on The Californer
- Long Beach Public Health Laboratory Now Offering Accredited Environmental Lead Testing Services
- French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
- Calder Capital's Growth Continues with Expansion into Southern California
- LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
- Moorpark College Wins 2025-26 Western State Conference Commissioner's Cup
This collaboration between MCI and GATC Health, with the backing of Lloyd's, marks a significant development in the insurance industry. It promises to reshape the landscape of clinical trial funding and provide stakeholders in the biotech industry with enhanced risk management tools to unlock groundbreaking medical innovations.
GATC Health's Multiomics Advanced Technology™ (MAT) platform, which utilizes AI and machine learning to simulate human physiology, has already shown promising results. In just two years, it has discovered and tested seven drug candidates with the potential to create 10 to 12 novel molecules each year. With this technology, the likelihood of clinical trial success is significantly increased.
The launch of this program marks a new era in clinical trial financing, where innovative technology and insurance come together to support medical innovation and bring life-changing treatments to those who need them most. With Lloyd's endorsement, this partnership between MCI and GATC Health is set to transform the drug development landscape for years to come.
Filed Under: Business
0 Comments
Latest on The Californer
- Impact & Influence March 2026: Joel Rodriguez Tirado - Why You're Still Waiting & The Power of Start
- New Comparison Helps Senior Travelers Weigh Overseas Adventure Travel Against Road Scholar
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Applications Now Open for the 2027 BrightEdge Entrepreneurs Program
- Mandeville Pests May Pose Serious Health Risks for Your Family
- xBxBio Advances Connected Cardiovascular Intelligence With Chapter 2 Release
- Share your workplace safety solutions at 2027 Applied Ergonomics Conference
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
- May The Worst Team Win! Loserball Kicks Off Another NFL Season of Hilarious Mayhem
- Wehb.pro Launches $99 AI Website Builder With No Subscription or Platform Lock-In
- Top 10 AI Trading Robots Beat Market targeting High-Margin Stocks at 155% Annualized Return for Retail Investors (NVDA, USAR)
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
- MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
- Boost Board Gives Daily Visibility to Fundraising Campaigns Stuck at Zero
- Hazel-E Celebrates the Premiere of "Keeping Up With Hazel-E" on Wave TV Network
- Talaria E-bike China Source Cuts Talaria Sting MX5 Pro Pricing by $700
- Disruptor Creations Options Untitled Feature Film Written by David Krumholtz and Johnny Markows
- Skin Health Expert and Nurse Practitioner Blossom Inuenwi Launches 'The Glow Brief' Podcast
- AristoPup Grooming Launches "Fresh Start Grooming Days" to Help Palm Springs Animal Shelter Dogs
- New Edition of Bestselling Book Reveals How Consciousness Shapes Your Genes